Long-term Real-World Evidence (RWE) studies face significant challenges when it comes to patient retention, for several reasons:
[1] Time Commitment: Participants in RWE studies are often required to participate over extended periods, sometimes even years. This long-term commitment may lead to decreased interest and attrition over time, especially if the participants do not see immediate benefits from their participation.
[2] Life Changes: Given the long-term nature of RWE studies, life events such as changes in health status, relocation, changes in personal or financial circumstances, or simply a change in priorities can influence a participant’s ability or desire to continue in the study.
[3] Perceived Burden: Depending on the design of the study, the level of participant engagement required can vary widely. Some RWE studies may require frequent hospital visits, self-reporting of data, regular lab tests, or other potentially time-consuming activities. The perceived burden of these requirements can negatively impact retention.
[4] Lack of Engagement: If participants feel that they are just data points and do not feel personally engaged or valued, they may be more likely to drop out of the study. Personal engagement strategies, regular communication, and feedback are therefore crucial to keep participants motivated.
[5] Privacy and Data Security Concerns: In the era of digital health data, participants might worry about the potential misuse of their personal health information, which may lead to dropouts.
[6] Inadequate Understanding: If the participants do not fully understand the importance of their role, the relevance of the research, or the potential benefits to them or to society, they may be less likely to continue in the study. Education and clear communication are key to ensuring participants understand these aspects.
To address these challenges, researchers are increasingly looking to use technologies and strategies that can improve the participant experience and maintain engagement over time, such as remote monitoring technologies, digital health platforms, personalized engagement strategies, and clear, ongoing communication about the value and impact of the study.
Share this story...
Real World Evidence (RWE) 101 – HIPAA
RWE 101 - HIPAA HIPAA (Health Insurance Portability and Accountability Act), enacted in 1996, is a federal law in the United States that establishes regulations for the protection of [...]
Real World Evidence (RWE) 101 – The Common Rule
RWE 101 - The Common Rule The Common Rule plays a significant role in the governance of observational studies. The Common Rule refers to a set of regulations and [...]
Real World Evidence (RWE) 101 – The Tuskegee Syphilis Study (the reason we have the Belmont Report and the Common Rule)
RWE 101 - The Tuskegee Syphilis Study (the reason we have the Belmont Report and the Common Rule) The Tuskegee Syphilis Study, conducted from 1932 to 1972, stands as [...]
Real World Evidence (RWE) 101 – Observational Study vs Non-Interventional Study
RWE 101 - Observational Study vs Non-Interventional Study In the context of real-world evidence (RWE), the terms "observational study" and "non-interventional study" are often used interchangeably to refer to [...]
Real World Evidence (RWE) 101 – Are Non-Interventional Studies Regulated?
RWE 101 - Are Non-Interventional Studies Regulated? Yes, non-interventional studies (NIS) are regulated. While the specific regulations and requirements may vary by country, there are generally guidelines and provisions [...]
Real World Evidence (RWE) 101 – Postmarket Requirements (PMR) vs Post-Authorisation Safety Studies (PASS)
RWE 101 - Postmarket Requirements (PMR) vs Post-Authorisation Safety Studies (PASS) In the context of real-world evidence (RWE) and regulatory frameworks, postmarket requirements (PMRs) and post-authorization safety studies (PASS) [...]







